Dongkoo Bio & Pharma Co., Ltd. (006620) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Dongkoo Bio & Pharma Co., Ltd. (006620:KRX), powered by AI.

Current Price
₩4,195
P/E Ratio
2.4
Market Cap
119.4B
Sector
Common Stock
What is the Dongkoo Bio & Pharma Co., Ltd. stock price forecast?

Dongkoo Bio & Pharma Co., Ltd. is currently trading at ₩4,195. View real-time AI analysis on Alpha Lenz.

What is Dongkoo Bio & Pharma Co., Ltd. insider trading activity?

View the latest insider trading data for Dongkoo Bio & Pharma Co., Ltd. on Alpha Lenz.

What is Dongkoo Bio & Pharma Co., Ltd.'s P/E ratio?

Dongkoo Bio & Pharma Co., Ltd.'s P/E ratio is 2.4.

Dongkoo Bio & Pharma Co., Ltd.

KRX · 006620
₩4,195+90(+2.19%)Market closedKRX regular session 09:00–15:30 KST
Ask about Dongkoo Bio & Pharma Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Dongkoo Bio & Pharma Co., Ltd. trades at a P/E of 2.4 (undervalued) with strong ROE of 39.1%.

Ask for details

Company Overview

Dongkoo Bio & Pharma Co., Ltd. operates in the pharmaceutical industry, focusing on developing and manufacturing a broad range of healthcare products. This company is primarily dedicated to advancing medical treatments and enhancing health outcomes through its robust portfolio of prescription and over-the-counter medications. Dongkoo Bio & Pharma impacts various sectors including dermatology, oncology, and gastroenterology, providing specialized solutions that cater to both domestic and international markets. As an integral player in the health care sector, the company leverages cutting-edge research and development to drive innovation and meet emerging medical needs. Dongkoo Bio & Pharma's commitment to quality and safety reinforces its role as a significant contributor to public health, enhancing lives by offering accessible and effective pharmaceutical products. Through strategic collaborations and continuous product development, the company holds a prominent position in enhancing the global pharmaceutical landscape.

CEO조용준
SectorCommon Stock
IndustryCommon Stock
0

Company Statistics

FY 2025

Profile

₩119,410,641,440Market Cap
₩242,687,805,570Revenue
28.46MShares Out
0Employees

Margins

59.54%Gross
8.99%EBITDA
3.81%Operating
25.31%Pre-Tax
20.67%Net

Valuation

2.38P/E
0.79P/B
0.49EV/Sales
10.41EV/EBITDA
-4.83P/FCF

Growth (CAGR)

7.57%Rev 3Yr
11.76%Rev 5Yr
-18.43%Op Inc 3Yr
3.97%Op Inc 5Yr
96.49%Net Inc 3Yr
40.57%Net Inc 5Yr

Returns

17.29%ROA
39.12%ROE
22.37%ROIC

Financial Health

₩21,560,933,820Cash & Cash Equivalents
₩162,629,483,460Net Debt
121.05%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Dongkoo Bio & Pharma Co., Ltd. (ticker: 006620) is a company listed on KRX in the Common Stock sector (Common Stock). Market cap is $119.4B.

The current price is ₩4,195 with a P/E ratio of 2.38x and P/B of 0.79x.

ROE is 39.12% and operating margin is 3.81%. Annual revenue is $242.7B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Dongkoo Bio & Pharma Co., Ltd. (006620) Stock Forecast 2026 ₩4,195 — Price, Financials & Analyst Targets | Alpha Lenz